Scholar Rock Holding (Scholar Rock Holding) Book Value per Share

: $2.96 (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

Scholar Rock Holding's book value per share for the quarter that ended in Dec. 2023 was $2.96.

During the past 12 months, Scholar Rock Holding's average Book Value Per Share Growth Rate was -41.10% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -27.10% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -3.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of Scholar Rock Holding was 9.90% per year. The lowest was -27.10% per year. And the median was 6.30% per year.

Scholar Rock Holding's current price is $14.99. Its book value per share for the quarter that ended in Dec. 2023 was $2.96. Hence, today's PB Ratio of Scholar Rock Holding is 5.06.

During the past 8 years, the highest P/B Ratio of Scholar Rock Holding was 24.47. The lowest was 0.84. And the median was 3.24.

Scholar Rock Holding Book Value per Share Historical Data

The historical data trend for Scholar Rock Holding's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scholar Rock Holding Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Book Value per Share

Get a 7-Day Free Trial

3.79

7.64

4.89

5.04

2.96

Scholar Rock Holding Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Book Value per Share	Get a 7-Day Free Trial															5.04	4.40	3.67	2.98	2.96

Competitive Comparison

For the Biotechnology subindustry, Scholar Rock Holding's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Scholar Rock Holding PB Ratio Distribution

For the Biotechnology industry and Healthcare sector, Scholar Rock Holding's PB Ratio distribution charts can be found below:

* The bar in red indicates where Scholar Rock Holding's PB Ratio falls into.

Scholar Rock Holding Book Value per Share Calculation

Scholar Rock Holding's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Book Value Per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(225.22	-	0.00)	/	75.98
	=	2.96

Scholar Rock Holding's Book Value Per Share for the quarter that ended in Dec. 2023 is calculated as:

Book Value Per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(225.22	-	0.00)	/	75.98
	=	2.96

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.

Scholar Rock Holding (NAS:SRRK) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.

Scholar Rock Holding Book Value per Share Related Terms

Thank you for viewing the detailed overview of Scholar Rock Holding's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Scholar Rock Holding (Scholar Rock Holding) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scholar Rock Holding Corp (NAS:SRRK) » Definitions » Book Value per Share

Comparable Companies

Traded in Other Exchanges

2QK:Germany

Address

301 Binney Street, 3rd Floor, Cambridge, MA, USA, 02142

Website

https://www.scholarrock.com

Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company primarily operates in the United States. The company's lead product candidate is Apitegroma which is a highly selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGF?1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.

Executives

Mo Qatanani	officer: SVP and Head of Research	301 BINNEY STREET, 3RD FLOOR, C/O SCHOLAR ROCK HOLDING CORP, CAMBRIDGE MA 02142
Caryn Parlavecchio	officer: CHRO	SCHOLAR ROCK HOLDING CORPORATION, 301 BINNEY STREET, 3RD FLOOR, CAMBRIDGE MA 02142
Junlin Ho	officer: General Counsel	301 BINNEY STREET, CAMBRIDGE MA 02142
Edward H Myles	director	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Samsara Biocapital Gp, Llc	10 percent owner	251 CHURCHILL AVENUE, PALO ALTO CA 94301
Srinivas Akkaraju	director	565 EVERETT AVENUE, PALO ALTO CA 94301
Invus Public Equities, L.p.	10 percent owner	C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, 30TH FLOOR, NEW YORK NY 10022
Tracey Sacco	officer: Chief Commercial Officer	301 BINNEY STREET, 3RD FLOOR, C/O SCHOLAR ROCK HOLDING CORP, CAMBRIDGE MA 02142
Richard Brudnick	director	BIOVERATIV INC., 225 SECOND AVENUE, WALTHAM MA 02451
Jing L. Marantz	officer: Chief Medical Officer	C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Jay T. Backstrom	officer: CEO-Elect	SCHOLAR ROCK HOLDING CORPORATION, 301 BINNEY STREET, 3RD FLOOR, CAMBRIDGE MA 02142
Amir Nashat	director	10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
Samsara Biocapital, L.p.	10 percent owner	628 MIDDLEFIELD ROAD, PALO ALTO CA 94301
Artal Group S.a.	10 percent owner	VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661
Artal International S.c.a.	10 percent owner	VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661